2023 World Conference on Lung Cancer (Posters)-P1.24. Prognostic Value of DNA Ploidy and Nucleotyping in Early-stage Non-small Cell Lung Cancer

P1.24. Prognostic Value of DNA Ploidy and Nucleotyping in Early-stage Non-small Cell Lung Cancer - PDF(Slides)

Pdf Summary

A study was conducted to determine the effectiveness of DNA ploidy, nucleotyping, and tumor-stroma ratio (TSR) in predicting disease progression in early-stage non-small cell lung cancer (NSCLC) patients. The study also investigated whether adjuvant chemotherapy could benefit patients with different nucleotyping profiles. The DNA ploidy, nucleotyping, and TSR were measured using chromatin structure typing analysis in 154 NSCLCs at stage I-II. Cox proportional hazard regression models were used to evaluate the associations of these biomarkers with disease-free survival (DFS) at 5 years. The biomarkers were then grouped together as combined indicators. Non-diploidy, chromatin heterogeneity, and a high TSR were considered risk factors for poor prognosis. Patients were categorized into low, medium, and high-risk groups based on the number of risk factors. The study found that among the patients, 66.2% had non-diploid DNA, 26.0% had chromatin heterogeneity, and 81.8% had a low TSR. During the follow-up period, 30.5% of patients experienced tumor recurrence or metastasis. Univariable analysis showed that non-diploidy was associated with a significantly lower 5-year DFS rate. After combining DNA ploidy and nucleotyping and adjusting for potential confounders, the high and medium-risk groups had a 4- and 3-fold increase in the hazard for disease progression or mortality compared to the low-risk group. In the high-risk group, adjuvant chemotherapy was associated with improved 5-year DFS. The study concluded that non-diploid DNA status and the combination of ploidy and nucleotyping can be useful prognostic indicators in early-stage NSCLC patients. Additionally, non-diploid NSCLC patients with chromatin heterogeneity might benefit from adjuvant chemotherapy.

Asset Subtitle

Luning Mao

Meta Tag

Speaker Luning Mao

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

DNA ploidy

nucleotyping

tumor-stroma ratio

NSCLC

disease progression

adjuvant chemotherapy

biomarkers

DFS rate

prognosis

chromatin heterogeneity